All eyes on PTC Therapeutics earnings after brutal Q4 miss
PTC Therapeutics is under scrutiny as it reports first-quarter earnings, with investors keen to see if the rare-disease biotech can recover from a significant Q4 miss. Analysts anticipate an improved performance, expecting a loss of 46 cents per share on revenue of $224.08 million, driven by the performance of its phenylketonuria therapy, Sephience. The report will also shed light on the company's path to profitability and its geographic expansion efforts for Sephience, especially after last quarter's revenue shortfall raised concerns about execution.
Can PTC Therapeutics (PTCT) Be A Bargain On Its Russell Index Additions?
PTC Therapeutics (PTCT) has gained attention due to its inclusion in several Russell indices, influencing fund flows. Despite a strong recent performance and an estimated 58% intrinsic discount, questions remain about whether its current trading price of $83.31 already accounts for future growth, especially concerning its rare disease pipeline. The company is considered 11.3% undervalued by a popular narrative, but its P/S ratio of 8.4x against a fair ratio of 4.8x suggests potential over-optimism.
Enterprise value to EBIT forward of PTC Therapeutics, Inc. – NASDAQ:PTCT
This article focuses on the enterprise value to EBIT forward for PTC Therapeutics, Inc. (NASDAQ: PTCT). It appears to be a financial data point or analysis on the TradingView platform for the biotechnology company. The content primarily lists navigation and branding information from TradingView, with the core financial data point likely housed within a chart or table not present in the provided text.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Catalyst Pharmaceuticals (CPRX) announced positive Phase I results for Agamree (vamorolone), indicating its potential for chronic inflammatory rare diseases beyond its current Duchenne muscular dystrophy (DMD) indication. The study showed Agamree delivers corticosteroid benefits with less immunosuppression than conventional corticosteroids. This news comes as Catalyst Pharmaceuticals is set to be acquired by Angelini Pharma for $4.1 billion, a deal expected to expand the commercialization of CPRX's therapies.
Form 4 PTC Therapeutics Inc For: 30 June By Investing.com
This article provides an SEC Form 4 filing for PTC Therapeutics Inc., specifically for June 30. It includes the company's stock symbol (PTCT) and indicates a slight increase in its share price. The content is brief, primarily serving as an official notification of the filing.
Form 4 PTC Therapeutics Inc For: 30 June By Investing.com
This article reports on a Form 4 filing for PTC Therapeutics Inc for the period ending June 30. Form 4s are SEC filings that disclose changes in company ownership by insiders. The article indicates that PTC Therapeutics Inc (PTCT) stock saw a 2.41% increase related to this news.
Form 4 PTC Therapeutics Inc For: 30 June By Investing.com
This article from Investing.com is a truncated report about a Form 4 filing for PTC Therapeutics Inc for June 30. The content mostly consists of navigation links, advertisements, and market data rather than detailed information about the filing itself. The core information provided is the company name, the document type, and the date.
Ptc therapeutics chief technical ops officer sells $693k in stock
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, Inc., sold over $693,000 worth of company stock on June 26, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan and occurred while PTCT stock was near its 52-week high, with InvestingPro analysis suggesting it is slightly overvalued. The sale follows recent positive Q1 2026 earnings for PTC Therapeutics, exceeding analyst expectations, and positive analyst ratings from Jefferies, TD Cowen, and BofA Securities.
Price to sales forward of PTC Therapeutics, Inc. – NASDAQ:PTCT
This article provides a financial snapshot of PTC Therapeutics, Inc. (NASDAQ: PTCT), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or an incomplete financial data page from TradingView, indicating that the market for PTCT is currently closed with no trades.
Enterprise value to EBITDA forward of PTC Therapeutics, Inc. – NASDAQ:PTCT
This article, published by TradingView, focuses on the Enterprise Value to EBITDA (EV/EBITDA) forward metric for PTC Therapeutics, Inc. (NASDAQ: PTCT). It likely provides financial data related to this metric, indicating the company's valuation relative to its earnings before interest, taxes, depreciation, and amortization. The article appears to be a snapshot of financial analysis available on the TradingView platform.
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Defensive Index
PTC Therapeutics, Inc. (NasdaqGS:PTCT) has been added to the Russell 2000 Defensive Index, as announced on June 28, 2026. The company is a global biopharmaceutical firm specializing in the discovery, development, and commercialization of medicines for rare disorders, with a diversified therapeutic portfolio including treatments for Duchenne muscular dystrophy and spinal muscular atrophy. Its stock price was 81.35 USD at market close on July 1, 2026.
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Growth-Defensive Index
PTC Therapeutics, Inc. (NasdaqGS: PTCT) has been added to the Russell 2000 Growth-Defensive Index. This announcement, published on June 28, 2026, at 09:55 pm EDT, was sourced from S&P Capital IQ. The company is a global biopharmaceutical firm specializing in developing and commercializing medicines for rare disorders, with products like Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi.
Price to earnings forward of PTC Therapeutics, Inc. – HAM:BH3
This article provides financial information for PTC Therapeutics, Inc. (HAM:BH3), specifically focusing on its forward price-to-earnings ratio. It indicates that the market for this stock was closed with no trades. The content is presented within the TradingView platform, noting that market data is provided by ICE Data Services and reference data by FactSet.
PTC Therapeutics (PTCT) Launches Sephience After Strong Early Sales And $500 Million Raise
PTC Therapeutics (PTCT) has launched Sephience, a new phenylketonuria treatment, reporting strong early sales and completing a $500 million convertible note offering to fund future development. The company is also engaged in a collaboration with Novartis, positioning it at a strategic point for investors in rare disease drug development. Key considerations for investors include Sephience's uptake, the deployment of the $500 million, and updates on the Novartis partnership, alongside risks such as negative shareholders' equity and recent insider selling.
Form 4 PTC Therapeutics Inc For: 26 June By Investing.com
This article from Investing.com reports on a Form 4 filing for PTC Therapeutics Inc for June 26. These filings typically detail changes in ownership of company stock by insiders. The article itself is very brief and confirms the date of the filing.
Form 4 PTC Therapeutics Inc For: 26 June By Investing.com
This article from Investing.com reports that a Form 4 filing for PTC Therapeutics Inc. was made on June 26. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their beneficial ownership of the company's securities. The brief article mentions the company's stock symbol PTCT and its current performance.
Form 4 PTC Therapeutics Inc For: 26 June By Investing.com
This article from Investing.com is a standard financial news brief announcing the filing of a Form 4 for PTC Therapeutics Inc. The filing date mentioned is June 26. These types of announcements are significant for investors as Form 4s detail changes in beneficial ownership of company stock by insiders.
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 5,323 Shares
PTC Therapeutics (NASDAQ:PTCT) insider Neil Gregory Almstead sold 5,323 shares of the company's stock on June 24th, part of multiple recent sales under a pre-arranged Rule 10b5-1 plan. Despite the insider selling, PTCT shares were down slightly but remain near their 52-week high, and the company recently exceeded quarterly revenue and earnings expectations. Analysts generally maintain a "Moderate Buy" rating for PTC Therapeutics with an average price target of $91.36.
Form 4 PTC Therapeutics Inc For: 26 June By Investing.com
This article from Investing.com announces a Form 4 filing for PTC Therapeutics Inc., dated June 26. The piece is brief and contains minimal content beyond the announcement itself. It also prominently features market data for various indices, commodities, and individual stocks.
PTC Therapeutics, Inc. Actuals & Estimates (NASDAQ:PTCT)
This article provides a detailed financial overview and analyst estimates for PTC Therapeutics, Inc. (NASDAQ:PTCT). It covers current stock performance, historical highs and lows, future price forecasts, and key financial metrics including earnings, revenue, EBITDA, and market capitalization. The company's next earnings report is expected on July 30, 2026, with analysts anticipating a positive surprise based on past performance.
PTC Therapeutics (PTCT) Launches Sephience After Strong Early Sales And $500 Million Raise
PTC Therapeutics (PTCT) has launched Sephience, a new phenylketonuria treatment, reporting strong early sales. The company also secured a $500 million convertible note offering to fund future business developments and is engaged in a collaboration with Novartis, indicating a period of significant change. Investors should monitor how PTC Therapeutics deploys its capital to support Sephience, advance pipeline projects, and pursue new business opportunities, as these decisions will heavily influence its risk and growth profile.
PTCT Forecast — Price Target — Prediction for 2027
This article provides a forecast for PTC Therapeutics, Inc. (PTCT) stock, including analyst price targets and future predictions. It details the company's financial performance, stock volatility, market capitalization, earnings reports, and technical analysis ratings. The article also answers frequently asked questions about PTCT's current stock price, historical highs and lows, and dividend policy.
Ptc therapeutics chief technical ops officer sells $1.92m in stock
PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold 23,749 shares of common stock for approximately $1.92 million after exercising options. This transaction, executed under a Rule 10b5-1 trading plan, occurred while the stock was trading near its 52-week high, with InvestingPro analysis suggesting it is overvalued. Despite this insider sale, recent company news includes strong Q1 2026 performance and positive analyst upgrades to a "Buy" rating.
Form 144 PTC THERAPEUTICS For: 24 June By Investing.com
The article, titled "Form 144 PTC THERAPEUTICS For: 24 June," primarily serves as a placeholder or financial notice from Investing.com regarding PTC Therapeutics. It reports the stock action for the named date, showing a 3.07% increase. The article itself contains minimal textual content beyond the headline and stock symbol, largely acting as a framework for displaying market data and related news suggestions.
Ptc therapeutics chief technical ops officer sells $1.92m in stock
Neil Gregory Almstead, Chief Technical Operations Officer at PTC THERAPEUTICS, INC. (NASDAQ:PTCT), sold 23,749 shares worth approximately $1.92 million on June 22, 2026, after exercising options. These sales were conducted under a Rule 10b5-1 trading plan. The timing of the sale is notable as the stock trades near its 52-week high, following a significant 65.5% return over the past year.
PTC Therapeutics SVP Christine Utter sells $1.49m common stock
Christine Marie Utter, SVP and Chief Accounting Officer at PTC Therapeutics (NASDAQ: PTCT), sold $1.49 million worth of common stock on June 17, 2026, after exercising stock options. This transaction, conducted via a Rule 10b5-1 trading plan, leaves her with 70,199 direct shares and 15,314 derivative shares. The sale occurred while PTCT shares were near their 52-week high, with the stock currently deemed overvalued by InvestingPro analysis, despite recent analyst upgrades and strong Q1 2026 earnings.
Form 4 PTC Therapeutics Inc For: 22 June By Investing.com
This article reports on a Form 4 filing for PTC Therapeutics Inc for June 22, as published by Investing.com. It indicates that the company's stock symbol is PTCT and includes a current price change of +0.96%. The article itself is very brief, mainly serving as an announcement for the filing.
Ptc therapeutics exec. vp and clo Mark Boulding sells $822,867
Mark Elliott Boulding, Executive Vice President and Chief Legal Officer at PTC Therapeutics, Inc., sold 10,462 shares of company stock for approximately $822,867, following the exercise of stock options for 10,522 shares. These transactions were executed under a Rule 10b5-1 trading plan. The sales occurred while PTCT stock was near its 52-week high, although InvestingPro suggested it was overvalued.
PTC Therapeutics Inc (PTCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for PTC Therapeutics Inc (PTCT), detailing its revenue by region. As of the latest update, the company's regional revenue shows the United States contributing 86.37% and non-US regions 13.63%, based on a reported $1.49 billion for the US and $235.89 million for non-US. Data for FY2025, FY2024, FY2023, FY2022, FY2021, FY2020, and FY2019 are noted as not yet disclosed.
PTC Therapeutics (PTCT) Stock Could Be 14% Undervalued After $500 Million Note Refinancing
PTC Therapeutics (PTCT) recently announced a $500 million private placement of convertible senior notes to refinance existing debt and fund general corporate needs. Despite recent share price volatility, the stock is estimated to be 14.2% undervalued, with a fair value of $91.57, driven by progress in its late-stage pipeline including therapies for Friedreich's ataxia and Huntington's disease. However, the company faces risks such as reliance on a few key products and ongoing losses that might lead to future fundraising and dilution.
PTC Therapeutics (PTCT) Stock Could Be 14% Undervalued After $500 Million Note Refinancing
PTC Therapeutics recently launched a $500 million private placement of convertible senior notes to refinance existing debt and support general corporate needs. Despite recent stock volatility and significant one-year returns, the stock is considered 14.2% undervalued, trading at $78.53 against an implied fair value of $91.57. This valuation hinges on progress in rare disease treatments and Huntington's disease, though risks like reliance on a few key products and ongoing losses remain.
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates
PTC Therapeutics Inc (PTCT) has an earnings forecast score of 7.50, ranking 100 out of 157 in the Pharmaceuticals industry, with an average analyst price target of $80.00. Based on 15 analysts, the current rating for PTCT is a "Buy", with anticipated upside space of 27.32%. The company's expected revenue for the next quarter is $293.06 million, and the EPS for the next quarter is projected to be $0.26.
PTC Therapeutics Jumps 7.7% Amid Sector-Wide Rally
PTC Therapeutics (PTCT) saw its shares climb 7.7% to $78.94 on Wednesday, driven by a broad rally across the biotechnology sector rather than specific company news. This synchronized movement, which included similar gains by other biotech firms, suggests a sector-wide capital rotation by investors. The rally pushed PTC's market capitalization to $6.5 billion, with trading volume reaching 1.2 million shares.
PTC Therapeutics prices $500M 0% convertible notes due 2031 to refinance 2026 notes
PTC Therapeutics has priced $500 million in 0% Convertible Senior Notes due 2031, with an option for initial purchasers to buy an additional $50 million. The net proceeds, estimated at $486.8 million (or up to $535.5 million if the option is exercised), will primarily be used to repurchase $222 million of existing 1.5% convertible notes due 2026. The new notes are unsecured, bear no regular interest, and are convertible at an initial price of approximately $107.48 per share.
Biotech PTC sells $500M 0% notes at 40% premium to stock
PTC Therapeutics announced the pricing of a private offering for $500 million in 0% Convertible Senior Notes due 2031, with an option for an additional $50 million. The net proceeds of approximately $486.8 million will primarily be used to refinance $222 million of their 1.5% Convertible Senior Notes due 2026 through a concurrent cash repurchase. The new notes have an initial conversion price of $107.48 per share, representing a 40% premium over the closing stock price on June 15, 2026.
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
PTC Therapeutics, Inc. (PTCT) announced a proposed offering of $500.0 million in Convertible Senior Notes due 2031 through a private placement. The company intends to use the net proceeds to repurchase or repay its 1.5% Convertible Senior Notes due 2026 and to repurchase approximately $50.0 million of its common stock. The offering aims to refinance existing debt and manage its capital structure.
PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes
PTC Therapeutics announced its plan to offer $500 million in convertible senior notes due in 2026. This offering aims to refinance existing 2026 notes, demonstrating the company's proactive approach to managing its debt
PTC Therapeutics plans $500M notes to refinance 2026 debt, buy stock
PTC Therapeutics announced a private offering of $500 million Convertible Senior Notes due 2031, with an option for an additional $50 million, to refinance its 1.5% Convertible Senior Notes due 2026. The company also plans to repurchase approximately $50 million of its common stock concurrently with the offering. This move aims to extend its debt maturity profile and manage its capital structure.
Sector Gamma AS Sells 56,189 Shares of PTC Therapeutics, Inc. $PTCT
Sector Gamma AS reduced its stake in PTC Therapeutics, Inc. by 47.6% in the fourth quarter, selling 56,189 shares, while insider selling by two executives also occurred recently. Despite this, PTC Therapeutics reported better-than-expected quarterly results with $272.55 million in revenue and an EPS of -$0.03, leading analysts to maintain a "Moderate Buy" consensus with an average price target of $91.36. The biopharmaceutical company focuses on therapies for rare genetic disorders and currently trades at $74.71, with institutional investors like Vanguard Group and Wellington Management Group increasing their positions.
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock By Investing.com
Eric Pauwels, CBO of PTC Therapeutics, sold approximately $1.6 million worth of company stock on June 10, 2026, after exercising stock options. This sale was executed under a Rule 10b5-1 plan, with shares trading at $75.00 each. The transactions follow a strong 47% return in PTCT shares over the past year and recent positive analyst upgrades, despite InvestingPro suggesting the stock might be overvalued.
PTC Therapeutics CBO Eric Pauwels sells $1.6 million in stock
PTC Therapeutics' Chief Business Officer, Eric Pauwels, sold 21,277 shares of company stock worth approximately $1.6 million on June 10, 2026, after acquiring 17,566 shares through stock option exercises. These transactions were executed under a Rule 10b5-1 plan. The sale follows a strong 47% return in PTCT shares over the past year and recent positive analyst upgrades and impressive Q1 2026 earnings.
PTC Therapeutics Insider Sold Shares Worth $1,595,775, According to a Recent SEC Filing
An insider at PTC Therapeutics recently sold shares valued at $1,595,775, as disclosed in a recent SEC filing. This transaction involved the sale of 48,150 shares at prices ranging from $33.15 to $33.25 per share.
PTC Therapeutics (PTCT) CBO sells shares under 10b5-1 trading plan
PTC Therapeutics' Chief Business Officer, Eric Pauwels, executed pre-planned trades under a Rule 10b5-1 plan. On June 10, 2026, he exercised options to acquire 17,566 shares at $18.01 each and subsequently sold 21,277 shares on the open market at $75.00 per share. Following these transactions, Pauwels directly holds 73,411 shares of Common Stock.
Does PTC Therapeutics' (PTCT) SEPHIENCE Momentum and Board Shift Reframe Its Commercial Strategy Narrative?
PTC Therapeutics reported record revenue from its drug SEPHIENCE while board member Alethia Young transitioned to an advisory role. This shift reinforces the company's focus on commercial expertise and strong SEPHIENCE uptake as it navigates challenges like the withdrawal of a Translarna NDA resubmission. Investors are now closely watching SEPHIENCE's scaling potential and the diversification of revenue through new programs like PTC518.
Los Angeles Capital Management LLC Has $2.46 Million Stock Position in PTC Therapeutics, Inc. $PTCT
Los Angeles Capital Management LLC reduced its stake in PTC Therapeutics by 31.7% in the fourth quarter, yet still holds 32,421 shares valued at approximately $2.46 million. Despite this reduction, PTC Therapeutics reported stronger-than-expected Q1 results with a reduced loss and increased revenue, contributing to a "Moderate Buy" consensus among analysts with an average price target of $91.36. Insider selling was noted, but other institutional investors increased their positions.
Key facts: PTC Therapeutics director resigns; posts record revenue
PTC Therapeutics (PTCT) announced that director Alethia Young resigned from the board effective June 8, 2026, and will continue as a consultant. The company also reported record revenue, driven by the global launch of SEPHIENCE, which saw strong patient uptake and expanding market penetration.
PTC Therapeutics (NASDAQ: PTCT) director Alethia Young shifts to consultant role
Alethia Young has resigned from the board of directors of PTC Therapeutics (NASDAQ: PTCT) effective June 8, 2026, due to other work commitments. Concurrently, she entered into a consulting agreement with the company as an advisor through June 8, 2027, receiving a monthly fee of $4,166.67. This transition ensures her continued advisory role without a board position.
PTCT Raised by Citigroup -- Price Target Increased to $108
Citigroup has upgraded PTC Therapeutics (PTCT) to a Buy rating and increased its price target to $108, signaling growing confidence in the company's future. Despite this positive analyst sentiment, GuruFocus considers PTCT significantly overvalued at its current price of $73.29, with insiders selling shares worth $3.0 million in the past three months. Investors are advised to consider both the analyst optimism and the valuation concerns and insider activity.
Citigroup Upgrades PTC Therapeutics to Buy From Hold, Raise Price Target to $108 From $76
Citigroup has upgraded PTC Therapeutics (PTCT) to a "Buy" rating from "Hold," simultaneously increasing its price target to $108 from $76. This positive revision comes as the biopharmaceutical company's shares are notably rising and follows other recent analyst upgrades after strong Q1 results. The article also provides a brief company profile for PTC Therapeutics, highlighting its focus on developing medicines for rare disorders.
19,877 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Commonwealth of Pennsylvania Public School Empls Retrmt SYS
The Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired 19,877 shares of PTC Therapeutics (NASDAQ:PTCT) valued at $1.51 million in the fourth quarter. This comes as PTC Therapeutics reported better-than-expected quarterly results with EPS of -$0.03 and revenue of $272.6 million, a 43.5% increase year-over-year. While analyst sentiment is a "Moderate Buy" with an $89 average price target, company insiders, including CEO Matthew B. Klein, have recently sold shares.
